search 2013 adfgs

News & Events

BioNJ Human Resource Conference on Culture Connection Taking Place on May 9

TRENTON, NJ (April 22) – Working from the theme The Culture Connection: Transforming and Creating Cultures that Thrive!, BioNJ, the trade association for New Jersey’s life science industry, will host its 3rd Annual Human Resource Industry Conference on May 9, 2014 from 8:00 a.m. to 5:00 p.m. at the Bridgewater Marriott in Bridgewater, NJ.

The Conference will bring together a variety of business leaders and recognized experts, all of whom bring a wealth of practical knowledge and experience.  Industry human resources professionals will benefit from this unique opportunity to network broadly, while at the same time gaining exposure to innovative initiatives happening now inside local New Jersey companies.

This year’s dynamic Keynote Speaker is Christine Roess, Founding Partner of SDI Communications.  She will provide insight from her work conducting transformational leadership training and executive coaching, as well as from her own fascinating life experiences in a presentation entitled, From Culture Consumer to Culture Creator: A 21st Century Paradigm.  The presentation will address the need for leadership and collaboration as organization hierarchies morph into flattened networks of living, breathing human beings who want to make a difference.

Four expert panels will share their perspectives on current trends and topics, which will include: On Our Radar – Legal Trends and Hot Topics, Impressive Beginnings – Innovative Practices in Onboarding and Branding; Getting it Right:  The Culture Equation – Views and Perspectives from across the Organization, and, The Culture Impact:  How Companies Are Influencing Culture through Performance Management Systems.

In addition, conference attendees will hear first-hand from experts and leaders from a wide variety of employers including Actavis, Celgene Corporation, Cornerstone Search Group , Covance, Drinker Biddle & Reath, Ferring Pharmaceuticals, Google, Ikaria, Insmed Incorporated, JBK Associates, Janssen Pharmaceuticals, Johnson & Johnson, Korn Ferry, Novartis, PTC Therapeutics and Reed Smith.

The Lead Sponsor for BioNJ’s HR Conference will be Cornerstone Search Group, whose client services include providing companies with customized & performance-based Executive Retained Search as effective and efficient alternatives to traditional Retained Search services.  Additional sponsors include, Joulé Clinical & Scientific Staffing Solutions, Scient Federal Credit Union and Scientific Search.  BioNJ’s HR Industry Conference provides a powerful opportunity for Human Resources leaders and their staffs to remain contemporary and to experience how other employers are cultivating initiatives to engage and inspire talent.

A limited number of discounted tickets are available for industry HR professionals who may be in-transition.  Please contact BioNJ for more information:

About BioNJ

With more than 300 member companies, BioNJ is focused on the growth and prosperity of New Jersey’s life sciences cluster. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.



Bill O’Donnell
(609) 890-3185, Ext. 117
(609) 802-3091

Rutgers begins new institution for research on infectious diseases

By Dan Goldberg/The Star-Ledger

NEWARK — Rutgers New Jersey Medical School is combining several research organizations into one new institute with the mission of detecting, treating and preventing infectious diseases, and focusing on the link between infectious and inflammatory diseases.

The Institute for Infectious and Inflammatory Diseases will enfold the Public Health Research Institute, the Center for Immunity and Inflammation and the Center for Emerging Pathogens, and will act as a springboard for research, according to a press release from the university.

Researchers at this new institute, according to the release, will look at the development of diseases with rapid detection of infectious agents and control of harmful inflammation as a major focus.

“We are establishing this institute, which brings together more than 250 scientists — many of them prominent in this field — to pursue a greater understanding of how the immune system and inflammatory responses contribute to a wide range of diseases,” said Christopher Molloy, interim chancellor of Rutgers Biomedical and Health Sciences. “We anticipate that their successes will produce dramatic progress against some of these diseases and keep the institute growing at a significant pace.”

The more specific goals of the new institute include:

• Developing new treatments, diagnostics and preventive measures for infectious and inflammatory diseases

• Moving new therapies and treatments from bench to bedside more quickly

• Helping to break the cycle of poverty and disease in impoverished communities locally and worldwide

• Offering continuing education to all health professionals as well as science writers and health educators

• Sharing research and information with the public through publications, blogs, social media and video

“Dysfunction of the immune system is increasingly recognized as contributing to a broad spectrum of infectious and noninfectious diseases,” said William Gause, senior associate dean for research at Rutgers New Jersey Medical School. “The specific focus of our new institute provides a unique opportunity to build an innovative and significant program of biomedical research excellence for Newark and the State of New Jersey.”


CNBC Ranks New Jersey #1 State for Education

In its 2013 Top States for Business, CNBC just confirmed what we already knew:  New Jersey has the absolute best education system in the country. The state improved from its #4 Education ranking in 2012. In addition, we remain in the top quartile of states for Workforce, Quality of Life, Technology and Innovation, and Access to Capital. New Jersey also continues to compete strongly in terms of Business Friendliness with California, New York, Pennsylvania, Ohio and Illinois.

Please click here to view the CNBC rankings.

Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi

 Life Science Industry Leaders and Innovator Companies Meet to Network and Identify Partnership Opportunities that Advance Personalized Medicine

TRENTON, NJ (May 8th, 2013)— BioNJ, the trade association for New Jersey’s biotechnology industry, is hosting its biggest and most interactive event of the year for companies involved in diagnostics and personalized medicine on June 6, 2013 at Sanofi’s US headquarters in Bridgewater, NJ.

Expanded this year due to the success of last year’s inaugural event, the 2013 BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies and emerging “innovator” companies for a full-day, interactive summit meeting.

We were delighted with the level of interest and participation in last year’s event,” said Debbie Hart, President of BioNJ. “So this year we are doing it bigger and better, extending the agenda to a full day and bringing in more first-class speakers from all key constituencies involved with diagnostics and personalized medicine. The BioNJ Diagnostics & Personalized Medicine Innovation Summit has quickly become a ‘must-attend’ event for anybody interested in this exciting new frontier of medicine, where a lot of New Jersey companies are leading the way.

Part of BioNJ’s ongoing Diagnostics & Personalized Medicine Initiative, the focus of this summit is to help participants identify opportunities for partnership, funding and growth while updating them on the latest trends, developments and challenges in the evolution and adoption of personalized medicine. All companies and individuals with an interest in diagnostics and personalized medicine are welcome to attend this event. The Summit will include company presentations and opportunities for one-on-one communication and interaction between leading global pharmaceutical and biotechnology companies, emerging diagnostics companies, funding organizations and life sciences company business development professionals.

Keynote speakers at the 2013 Summit include leaders from global life sciences companies as well as the investment community:

G. Steven Burrill
Chief Executive Officer, Burrill & Company

Elias Zerhouni, MD
President, Global R&D, Sanofi

In addition to keynote speakers, the agenda includes a series of moderated interactive panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Sanofi is fully committed to researching, developing and introducing new products and technologies that deliver on the promise of personalized medicine, and we are excited to be part of this BioNJ event,” said Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform at Sanofi, and a Board Member of BioNJ. “Better patient outcomes through more precise diagnostics, targeted therapies, increased efficiencies in healthcare delivery, and lower healthcare costs are just a few examples of how personalized medicine could transform healthcare, and our organization is working hard worldwide to contribute to this transformation.

The BioNJ Diagnostics and Personalized Medicine Committee, which has created the BioNJ Diagnostics & Personalized Medicine Innovation Summit, is also planning additional events focusing on diagnostics and personalized medicine, and will be announcing details for future events on its web site,

About the BioNJ Diagnostics Committee

The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey.

The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.

About BioNJ

With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster.  Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.

BioNJ To Host 2nd Annual Life Sciences Industry HR Conference On May 20

TRENTON, NJ (April 30, 2013)Due to the popularity and success of its 2012 event, BioNJ is pleased to announce it will host the 2nd Annual Human Resource Conference on Monday, May 20, 2013, from 8:00 a.m. to 5:00 p.m. at the Hilton East Brunswick Hotel, East Brunswick, NJ.  This year’s theme will focus on the concept of Transition & Transformation:  Proactive Strategies for Life Sciences.

A dynamic opening panel of senior leaders will share perspectives on the topic of Leadership During Times of Transition and Transformation to kick off the agenda.  The panel will be moderated by Chris Martin, Senior Vice President, Enterprise Solutions for Randstad Professionals and will include Karen A. DiSanto, Associate Vice President, Human Resources of Ferring Pharmaceuticals; Bill Mann, CEO of Helsinn Therapeutics, Inc.; Francois Nader, M.D., President and CEO of NPS Pharmaceuticals, Inc.; and Joan Winterbottom, Senior Vice President, Human Resources of Amicus Therapeutics, Inc.

This powerful panel will discuss leadership during times of transition and transformation and will focus on the impact that human resources can have on an organization’s journey through significant change.

Read more »

Quantex Laboratories Officially Opens New Facility, Confirms Commitment to NJ Life Sciences Industry


Cranbury, NJ – April 30, 2013 - – Quantex Laboratories, Inc., state officials, community representatives and customers today celebrated the official opening of Quantex Laboratories’ new facility at 3000 Eastpark Boulevard in Cranbury, New Jersey.  The 15,000-square foot space allowed Quantex to expand its services to include microbiological testing capabilities to its contract laboratory and analytical testing CRO services.

“The new facility enables us to offer our clients a broader range of services,” said Dr. James Menoutis, President and CEO of Quantex. “It also allows us to add employees and increase our business volume.”

Read more »

Monmouth County High School Named Among Country’s Top 10 Public High Schools

By Jeanette Rundquist/The Star-Ledger

FREEHOLD — Biotechnology High School — part of the Monmouth County Vocational School District — has been named one of the top ten public high schools in the country, according to U.S. News & World Report.

The life science- and research-focused school, one of five specialized career academies offered by the Monmouth County vocational district, was also cited in the ranking last year. It jumped up nine slots on the list this year, to land in eighth place.

Read more »

Competitive Solicitation for Life Sciences/Healthcare IT Accelerator Program Manager

The New Jersey Economic Development Authority (“Authority”) is seeking qualifications and solicitation submissions from well-qualified applicants to manage a Life Sciences/Healthcare IT Accelerator in New Jersey. This accelerator will be hosted at the Authority’s Commercialization Center for Innovative Technologies (‘CCIT’) in North Brunswick, NJ.

To review the full Competitive Solicitation, and all requirements, please click here.

The NJ Life Sciences/Healthcare IT Accelerator Initiative is conceived as a mentorship-driven, seed and early-stage investment fund based on initiatives in other states that have successfully engaged the community to support promising entrepreneurs interested in advancing Healthcare Information Technology and/or one of the many segments of the Life Sciences Industry. The Initiative will aim to provide a competitive environment focused on allowing entrepreneurs to showcase their products, ideas and business acumen in a mentor driven program for an opportunity to receive funding, mentorship and build key partnerships.

Read more »

NORD, BioNJ and Patient Advocacy Groups to Collaborate on Rare Disease Day Event at New Jersey State House

TRENTON, NJ (February 13, 2013) — The National Organization for Rare Disorders, BioNJ and 11 New Jersey-based patient advocacy groups are joining forces for a unique educational event about rare diseases to be held at the New Jersey State House on March 4, 2013. The gathering, which will convene local leaders from government, non-profit, and the biotechnology sector, will be conducted on behalf of state residents living with rare diseases that plague nearly 1 in every 10 Americans. The event is highlighted by a New Jersey success story – the latest in-state biopharmaceutical company to offer a significant treatment advance for one group of patients with a rare intestinal disorder.

Patients, researchers, health care advocates, members of the New Jersey government and biotech industry, as well as concerned citizens are invited to attend the event on Monday, March 4, 2013, from 11:30 a.m. to 12:30 p.m. at Committee Room 11, 4th floor, Annex Building, New Jersey Statehouse.

Read more »

Governor Chris Christie Acts to Spur Investment and Growth in New Jersey’s Innovative and Emerging Technology Businesses

 $25 Million Angel Investor Tax Credit Program Will Encourage Early Investment in New Jersey’s Emerging Innovative Businesses    

TRENTON, N.J. – Continuing his commitment to implement pro-growth initiatives and targeted, job-creating tax relief to invest in New Jersey’s economic development, Governor Christie today signed legislation creating an angel investor tax credit program to spur job creation and growth in New Jersey’s current and next generation of high-skill, high-wage emerging technology industries.

The bill, S-581, provides tax credits for up to 10 percent of a qualified investment in an emerging technology business with a physical presence in New Jersey and that conducts research, manufacturing, or technology commercialization in the state. New Jersey does not presently offer credits against either the corporate business tax or gross income tax for investments in emerging industries.

Read more »

Christie Administration Seeks Partner to Help State Create Life Sciences/Healthcare IT Accelerator

TRENTON, N.J. (Feb. 12, 2013) – The Christie Administration is looking to tap into the expertise of the private sector to bolster New Jersey’s status as a leader in life sciences and healthcare technology.  To help the industry’s most promising entrepreneurs deliver products to market, the New Jersey Economic Development Authority (EDA) today announced that it will launch a Life Sciences/Healthcare IT Accelerator and secure a private partner to manage the effort.

“Governor Christie recognizes how important it is to nurture the growth of New Jersey’s early-stage life sciences and technology companies, and this is another opportunity for the state to partner with the private sector to fill a market need,” said EDA Chief Executive Officer Michele Brown.  “The Life Sciences/Healthcare IT Accelerator will allow us to capitalize on the talent in our region and provide an environment that catalyzes innovation, entrepreneurship and job creation.”

Read more »

BioNJ Installs New Chair, Members on its Board of Trustees

EAST BRUNSWICK, NJ (February 13, 2013)– BioNJ, the voice of more than 350 biotech companies located in New Jersey, installed a new chairman and several new board members at its 20th Annual Meeting here last week.

The Board took the action at BioNJ’s 2013 Annual Meeting, Awards Program and Networking Event at the Hilton East Brunswick on Thursday, February 7, where some 700 industry leaders and associates turned out to celebrate the organization and the industry with a dinner, roundtable discussion and awards presentations.

New Jersey Lt. Governor Kim Guadagno served as the keynote speaker for the event.  She praised the life sciences industry’s economic and social contributions to the state’s well-being and pledged the continued support of the administration of Governor Chris Christie.

Read more »

NJ Governor Chris Christie Recognized as BIO 2012 Governor of the Year

We are pleased to report that New Jersey Governor Chris Christie was honored as the BIO 2012 Governor of the Year. The BIO Governor of the Year Award honors a governor who has demonstrated outstanding leadership in support of the biotechnology industry.

Please see below of a video in which Governor Christie made his acceptance speech following a presentation of the award by BIO Board Member and Celgene Executive Vice President and Chief Operations Officer Perry A. Karsen and BioNJ President Debbie Hart. Read more »

BioNJ Joins Effort to Bring Life Science Education, Workforce Training and Entrepreneurship to the National Stage

BOSTON (June 20, 2012)-BioNJ, the trade association for New Jersey’s thriving biotechnology industry, has joined 40 other state bioscience organizations in a nationally coordinated effort to ensure that the United States will continue its global leadership in bioscience innovation by developing and delivering industry-led life science education, workforce development and entrepreneurship programs across the county.

BioNJ has signed on to be a member of this newly established group – the Coalition of Bioscience Institutes (CSBI). The formation of CSBI was announced at the 2012 BIO International Convention, the industry’s global event for biotechnology that is hosted by the Biotechnology Industry Organization (BIO). Read more »

NJ Lt. Governor and BioNJ Honor NJ Student for Top Honors at International Biology Olympiad during BIO International Convention

BioNJ President Debbie Hart, left, and Lt. Governor Kim Guadagno, right, congratulate Rebecca Shi, for her outstanding achievements at the 2011 International Biology Olympiad.

BOSTON - (June 20, 2012) A New Jersey teen who as a high school senior earned top honors at the 2011 International Biology Olympiad was honored yesterday by New Jersey Lt. Governor Kim Guadagno and BioNJ President Debbie Hart at a special ceremony here during the world’s largest annual biotechnology conference. Read more »

New Jersey among Top States under Qualifying Therapeutic Discovery Project

TRENTON, NJ (Nov. 3, 2010) – BioNJ President Debbie Hart issued the following statement today following the announcement by U.S. Treasury Secretary Timothy Geithner and Health and Human Services Secretary Kathleen Sebelius of the recipients of the $1 billion Therapeutic Discovery Project: Read more »

New Jersey Biotechnology Continues to See Growth

Number of NJ Companies Continues to Increase in Latest Survey
Early-Stage Funding a Continuing Issue

TRENTON, NJ (June 10, 2010) ─ The number of biotechnology companies operating in New Jersey continues to increase significantly despite the downturn in the economy, ongoing difficulties in obtaining venture capital and other forms of funding and a contraction in the biotechnology and pharmaceutical industries at both the state and national levels, according to initial results from an industry survey released today by BioNJ, the trade association for the biotechnology industry in New Jersey. Read more »

BioNJ Holds New Jersey’s Only BioPartnering Conference on June 14-15 in Princeton

TRENTON, NJ (June 7, 2010) – BioNJ, New Jersey’s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. Read more »

Greater Philadelphia Region Life Sciences Cluster Attains Top Rankings

A comparative study conducted by the Milken Institute ranks the Greater Philadelphia region second in the study’s Overall Composite Index, after only Boston and ahead of Greater San Francisco.
Read more »

BioNJ Welcomes New and Returning Members to the Board of Trustees

TRENTON (January 28, 2010) – At its 17th Annual Meeting on January 28, BioNJ’s Board of Trustees announced the appointment of three new board members, and reappointment of five board members. The mission of the Board is to help foster a positive culture for biotechnology companies to prosper in New Jersey. Read more »

BioNJ Elects New Officers; Adds Five New Members to Board of Trustees

TRENTON (January 23, 2009) — BioNJ, New Jersey’s trade association for bioscience companies, announced today that at its January 22, 2009 Annual Meeting, Dinner and Awards Program the Board of Trustees named new officers and elected five new members. The mission of the Board is to help foster a positive culture for biotechnology companies to prosper in New Jersey. Read more »

BioNJ Presents 2nd Annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to Genmab CEO, Lisa N. Drakeman, Ph.D.

TRENTON (January 22, 2009) — BioNJ, New Jersey’s trade association for bioscience companies, announced today that the second annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership had been awarded to Lisa N. Drakeman, Ph.D., who is Chief Executive Officer of Genmab of Princeton, NJ. Read more »